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Abstract Cogan’s syndrome is characterized by non-
infectious, interstitial keratitis combined with a vestib-
ulo-auditory deWcit. Despite therapy with corticoster-
oids in combination with immunosuppressive agents,
relapses occurred in two subjects and the clinical
course suggested a progression of the disease. Treat-
ment with anti-TNF- was started leading to a rapid
and sustained clinical remission for over 2 respectively
3 years.
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Introduction
Characteristic manifestations of Cogan’s syndrome
described for the Wrst time in 1945 [1] are a non-infec-
tious, interstitial keratitis combined with a vestibulo-
auditory deWcit. Associations with aortitis and sys-
temic vasculitis have been described. The Cogan syn-
drome commonly occurs in adults in the third decade
of life [1]. In approximately half of the patients’ eye
involvement, and in one-third inner ear disorders are
the Wrst symptoms [2, 3]. Besides interstitial keratitis
causing eye redness, blurred vision, photophobia and
pain, other parts of the eye may also be involved lead-
ing to conjunctivitis, iridocyclitis, scleritis or retinitis.
Ear involvement often goes along with hearing loss,
vertigo or ataxia and can cause nausea or vomiting. To
prevent persistent deafness and other sequels due to
this inXammatory process, commonly corticosteroids
and other immunosuppressive agents are used for
treatment [4]. In this article we describe the cases and
further courses in two patients with Cogan’s syn-
drome, we reported before [5]. Because of the relapse
of the illness, as often seen in Cogan’s patients, ther-
apy was changed to TNF- inhibitor and led to a
remission.
Case reports
Case 1 (F.P. 1967)
In November 2000 diagnosis of Cogan’s syndrome was
made in a 33-year-old man based on a bilateral pro-
gressive hearing loss, tinnitus and ataxia, as well as a
bilateral interstitial keratitis following a viral infection
of the upper airways. A therapy with topical ocular and
systemic corticosteroids (1 mg/kg body weight)
resulted in a rapid improvement of the eye manifesta-
tions. However, hearing loss and ataxia became worse.
Because of a severe maculopapular exanthema, ther-
apy with azathioprine 150 mg daily was stopped after
3 weeks and cyclophosphamide 1 g as pulse-therapy
was given intravenously from January till June 2001.
While the hearing on the right side did not recover, the
left side improved partially. Although the patient
remained on a maintenance therapy with prednisone
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494 Rheumatol Int (2007) 27:493–49520 mg per day, a relapse with an acute hearing loss of
the left side occurred in July 2002. Intravenous cyclo-
phosphamide therapy was immediately restarted, and
prednisone dose was increased to 100 mg per day.
However, due to insuYcient therapeutic eVect, an infu-
sion of inXiximab (300 mg) was given in April 2003.
Within a few days following the Wrst infusion, an
improvement of the hearing loss to the pre-relapse
state was achieved. InXiximab 300 mg was given in
monthly intervals, oral prednisone was reduced gradu-
ally and completely stopped in February 2004. Because
the hearing conditions remained stable, inXiximab
therapy has been extended to a 10 week and Wnally a
3 month interval. Hearing and vestibular conditions
remained stable (Fig. 1) and showed a favourable
course with the patient in an otherwise good health
doing regularly sports like playing squash, running or
biking. This condition is now remaining pleasant for
1 year without any therapy.
Case 2 (X.D. 1951)
Within a few weeks, isolated bilateral hearing loss
developed in this 49-year-old man. Nine months later,
in June 2000, recurrent fever, arthralgias and severe
bilateral nodular scleritis occurred. Oto-neurological
examination showed a two-sided sensorineural hearing
loss in the high frequency tones, and a unilateral
peripheral vestibular deWcit with a caloric hyporeXexia
on the left side. In November 2000 due to persisting
subfebrility, echocardiography revealed a mild aortic
insuYciency. The diagnosis of Cogan’s syndrome was
Wnally made, and therapy with oral prednisone was
started at a daily dose of 2 mg/kg. While hearing loss
improved, fever persisted and the ocular manifesta-
tions progressively worsened. Oral cyclophosphamide
(2 mg/kg body weight) was added 1 month later.
Episcleritis and scleritis then completely resolved
within 6 weeks, subsequently prednisone was reduced
to 5 mg per day. Although treatment with cyclophos-
phamide was continued, scleritis recurred in January
2002. Infusion with inXiximab 300 mg was started in
January 2002, and repeated every 6 weeks. Due to per-
sistent arthralgias leXunomide 20 mg per day was
added. Thereafter ocular manifestations completely
disappeared and did not recur. Oral prednisone was
continuously tapered and discontinued in May 2003.
InXiximab dose was increased to 400 mg and the inter-
val was prolonged to 8 weeks. Hearing function
remains stable, especially a transient subjective and
objective improvement can be seen 1 week after the
infusion of inXiximab (Fig. 2).
Discussion
Cogan’s syndrome is an inXammatory disease of
unknown origin. Study results indicate an autoimmune
pathogenesis. A decade ago, antibodies against corneal
and inner ear tissue have been detected [6¡8]. More
recently, antibodies against a peptide-antigen have been
found in sera from patients with Cogan’s syndrome.
These peptide-antigens share sequence homology with
CD148 and connexin 26 that are expressed in the inner
ear [6]. In addition, histopathological examination of
corneal tissue and cochlea from patients with Cogan’s
disease also showed lymphocytic and plasma cell inWl-
tration suggesting a cell-mediated reaction [6, 9].
Because hearing loss usually is bilateral and progres-
sive and eventually results in deafness (up to 60%) [9],
early treatment is essential. Several publications report
that treatment with corticosteroids as mono-therapy
may fail, but combination therapy with immunosup-
pressants such as cyclophosphamide, cyclosporine or
Fig. 1 Course of hearing function in pure tone audiogram of case 1
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Rheumatol Int (2007) 27:493–495 495methotrexate may lead to favourable outcomes [4, 10–
13]. However, even in patients with early immunosup-
pressive treatment, hearing improvements is often
incomplete [5]. This may be due to insuYcient concen-
trations of drugs at the aVected sites.
As both of our patients did not respond satisfacto-
rily to a combined therapy of oral prednisone and
cyclophosphamide, or even relapsed under established
treatment, inXiximab, a chimeric monoclonal antibody
against TNF- was given. As shown earlier, this anti-
inXammatory and immunosuppressive strategy may
show rapid and sustained eVects in various inXamma-
tory syndromes [13, 14].
Therapy with inXiximab was well tolerated in both
patients. Although in one patient the interval was
extended up to 3 months and immunosuppressive ther-
apy was now stopped for 1 year, no relapse of the
Cogan syndrome was observed. In conclusion treat-
ment with the TNF- inhibitor inXiximab appears to be
eVective in inducing and maintaining remission in
patients with therapy-resistant Cogan’s syndrome.
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Fig. 2 pure tone audiogram in case 2 immediately before and 7 days after infusion of inXiximab
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